Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Marchesi, F; Salmanton-García, J; Emarah, Z; Piukovics, K; Nucci, M; López-García, A; Ráčil, Z; Farina, F; Popova, M; Zompi, S; Audisio, E; Ledoux, MP; Verga, L; Weinbergerová, B; Szotkovski, T; Da, Silva, MG; Fracchiolla, N; De, Jonge, N; Collins, G; Marchetti, M; Magliano, G; García-Vidal, C; Biernat, MM; Van, Doesum, J; Machado, M; Demirkan, F; Al-Khabori, M; Žák, P; Víšek, B; Stoma, I; Méndez, GA; Maertens, J; Khanna, N; Espigado, I; Dragonetti, G; Fianchi, L; Del, Principe, MI; Cabirta, A; Ormazabal-Vélez, I; Jaksic, O; Buquicchio, C; Bonuomo, V; Batinić, J; Omrani, AS; Lamure, S; Finizio, O; Fernández, N; Falces-Romero, I; Blennow, O; Bergantim, R; Ali, N; Win, S; Van, Praet, J; Tisi, MC; Shirinova, A; Schönlein, M; Prattes, J; Piedimonte, M; Petzer, V; Navrátil, M; Kulasekararaj, A; Jindra, P; Sramek, J; Glenthøj, A; Fazzi, R; De, Ramón-Sánchez, C; Cattaneo, C; Calbacho, M; Bahr, NC; El-Ashwah, S; Cordoba, R; Hanakova, M; Zambrotta, G; Sciumè, M; Booth, S; Rodrigues, RN; Sacchi, MV; García-Poutón, N; Martín-González, JA; Khostelidi, S; Gräfe, S; Rahimli, L; Ammatuna, E; Busca, A; Corradini, P; Hoenigl, M; Klimko, N; Koehler, P; Pagliuca, A; Passamonti, F; Cornely, OA; Pagano, L, , EPICOVIDEHA, working, group.
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).
Haematologica. 2023; 108(1):22-33 Doi: 10.3324/haematol.2022.280847 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Hönigl Martin

Prattes Jürgen

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Adult - administration & dosage

Follow-Up Studies - administration & dosage

COVID-19 Testing - administration & dosage

COVID-19 - administration & dosage

Leukemia, Myeloid, Acute - therapy, drug therapy

Hematology - administration & dosage

© Med Uni Graz • Imprint